This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kimmig, A. Articles by Niethammer, D. Search for Related Content PubMed PubMed Citation Articles by Kimmig, A. Articles by Niethammer, D.

Susceptibility of Multidrug-resistant Human Leukemia Cell Lines to Human Interleukin 2-activated Killer Cells

Department of Hematology and Oncology, Children's University Hospital [A. K., R. H., G. K., D. N.], and Physiological Chemistry [V. G., G. F., M. N.], University of Tuebingen, Tuebingen, and Medical Laser Center, Luebeck [H. D.], West Germany

Considering the possibility to overcome drug resistance by other treatment strategies than chemotherapy we investigated the susceptibility of three independently selected multidrug-resistant sublines of the T-lymphoblastoid leukemic cell line CCRF-CEM to lymphokine-activated killer (LAK) cells. We found that two of the multidrug-resistant sublines were significantly less susceptible targets to LAK cells. A third one, however, was as susceptible as the parental CCRF-CEM cell line. Moreover, a multidrug-resistant subline that reverted to an almost drug-sensitive phenotype was observed to be also revertant for resistance against LAK cells. We found an inverse relationship between the expression of the mdr1 gene (P-glycoprotein) and the susceptibility of LAK cells. Verapamil, a calcium channel blocker, while increasing the drug sensitivity of a multidrug-resistant subline, did not induce a reversal of the suppression of LAK susceptibility. The possibility of enhanced resistance to LAK cells of multidrug-resistant cells should be taken into account when one is looking for therapy strategies to overcome multidrug resistance.

¹ To whom requests for reprints should be addressed, at Children's University Hospital, Ruemelinstrasse 21-23, D-7400 Tuebingen 1, West Germany.

Received 10/17/89. Accepted 8/ 3/90.

This article has been cited by other articles:

				T. Efferth, V. B. Konkimalla, Y.-F. Wang, A. Sauerbrey, S. Meinhardt, F. Zintl, J. Mattern, and M. Volm Prediction of Broad Spectrum Resistance of Tumors towards Anticancer Drugs Clin. Cancer Res., April 15, 2008; 14(8): 2405 - 2412. [Abstract] [Full Text] [PDF]

				T. Efferth, S. Kahl, K. Paulus, M. Adams, R. Rauh, H. Boechzelt, X. Hao, B. Kaina, and R. Bauer Phytochemistry and pharmacogenomics of natural products derived from traditional chinese medicine and chinese materia medica with activity against tumor cells Mol. Cancer Ther., January 1, 2008; 7(1): 152 - 161. [Abstract] [Full Text] [PDF]

				A. Skladanowski, M.-G. Come, M. Sabisz, A. E. Escargueil, and A. K. Larsen Down-Regulation of DNA Topoisomerase II{alpha} Leads to Prolonged Cell Cycle Transit in G2 and Early M Phases and Increased Survival to Microtubule-Interacting Agents Mol. Pharmacol., September 1, 2005; 68(3): 625 - 634. [Abstract] [Full Text] [PDF]

				J.-P. Gillet, T. Efferth, D. Steinbach, J. Hamels, F. de Longueville, V. Bertholet, and J. Remacle Microarray-based Detection of Multidrug Resistance in Human Tumor Cells by Expression Profiling of ATP-binding Cassette Transporter Genes Cancer Res., December 15, 2004; 64(24): 8987 - 8993. [Abstract] [Full Text] [PDF]

				T. Efferth, A. Sauerbrey, A. Olbrich, E. Gebhart, P. Rauch, H. O. Weber, J. G. Hengstler, M.-E. Halatsch, M. Volm, K. D. Tew, et al. Molecular Modes of Action of Artesunate in Tumor Cell Lines Mol. Pharmacol., August 1, 2003; 64(2): 382 - 394. [Abstract] [Full Text] [PDF]

				C. Borchers, R. Boer, K. Klemm, V. Figala, T. Denzinger, W.-R. Ulrich, S. Haas, W. Ise, V. Gekeler, and M. Przybylski Characterization of the Dexniguldipine Binding Site in the Multidrug Resistance-Related Transport Protein P-Glycoprotein by Photoaffinity Labeling and Mass Spectrometry Mol. Pharmacol., June 1, 2002; 61(6): 1366 - 1376. [Abstract] [Full Text] [PDF]

				A. A. Shtil, J. G. Turner, J. Durfee, W. S. Dalton, and H. Yu Cytokine-Based Tumor Cell Vaccine Is Equally Effective Against Parental and Isogenic Multidrug-Resistant Myeloma Cells: The Role of Cytotoxic T Lymphocytes Blood, March 15, 1999; 93(6): 1831 - 1837. [Abstract] [Full Text] [PDF]